Methylene Blue

Methylene Blue is one of the oldest synthetic pharmaceuticals overall - developed in 1876 by the German chemist Heinrich Caro, originally as a textile dye. Shortly after it became the first fully synthetic drug against malaria and remains clinically approved today for the treatment of methemoglobinemia.

Since the 2010s it has seen a research renaissance - as a mitochondrial booster, cognition compound and antioxidant in the low dose range. We sell it as an oral tablet at 20mg each. Pharmaceutical purity (USP grade) is required - industrial methylene blue contains heavy metal impurities and is not suitable for oral use.

Methylene Blue is a redox modulator. In the mitochondria it acts as an alternative electron carrier: when Complex I of the respiratory chain is weakened - typical under oxidative stress or with aging - MB takes over and delivers electrons directly to Complex III. ATP production keeps running, the cell stays energetically supplied.

Additionally it acts as a nitric oxide synthase inhibitor and as an antioxidant at low doses. At higher doses the effect flips - the molecule itself becomes a pro-oxidant. Hence the narrow therapeutic window that defines any sensible use.

Two routes - pick what fits your day:

• Swallowed: tablet with some water, dissolves in the stomach. Slower onset, but no blue mouth.
• Sublingual: let the tablet dissolve under the tongue. Faster onset and higher bioavailability because first-pass metabolism in the liver is skipped. The mouth turns visibly blue for a while though.

Both routes work systemically. Once daily, ideally in the morning - Methylene Blue is mildly stimulating and can disrupt sleep if taken in the evening.

Methylene Blue follows a classic inverted U-shaped dose response curve. At low doses it acts as a pro-energetic and antioxidant. Above a certain threshold the effect flips - the molecule becomes a pro-oxidant and can do more harm than good.

The hard rule: stay below 0.5 mg per kg body weight. More is definitely not better here. That is not just a caution rule but baked into the mechanism itself.

Methylene Blue is one of the oldest and most intensively studied drugs overall. Modern research investigates it in three main directions:

• Mitochondrial booster: alternative electron source in the respiratory chain when Complex I is weakened (Tucker et al., 2018).
• Neuroprotective: in animal models MB improves memory and protects against oxidative stress in brain cells (Riha et al., 2005; Rojas et al., 2012).
• Tau aggregation inhibitor: methylthioninium, the active moiety of methylene blue, was tested in an exploratory phase 2 trial for Alzheimer's (Wischik et al., 2015).

The data on low-dose MB in healthy adults is much smaller than the data on clinical applications. Much is experience from the biohacker community plus solid preclinical mechanism data.

Methylene Blue is a potent MAO inhibitor. Combining it with SSRIs, SNRIs, MAOIs or other serotonergic substances can trigger serotonin syndrome - a medical emergency, not a theoretical risk.

The US prescribing information carries a boxed warning on this: together with SSRIs, SNRIs, MAO inhibitors or opioids, methylene blue can trigger serious, even fatal serotonin syndrome.

Anyone currently on antidepressants or recently discontinued: strictly avoid Methylene Blue. This combination is non-negotiable.

• Blue coloration: mouth (with sublingual use) and urine turn blue. Harmless, normal, gone within 12-24 hours.
• Occasional mild nausea or headache, especially when escalating too fast.
• At too high a dose (above 0.5 mg/kg body weight): the effect flips into pro-oxidant - the exact opposite of what you want.
• G6PD deficiency: according to the prescribing information, methylene blue must not be used with a deficiency of the enzyme G6PD, as it can destroy red blood cells (hemolytic anemia).

Store dry, cool and protected from light - Methylene Blue is light-sensitive. Keep the original container closed and out of reach of children.